Artificial miRNA Construct for Sustained Chronic Inflammation Suppression

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current therapeutic agents for chronic inflammation, such as steroidal and non-steroidal anti-inflammatory drugs, are insufficient in effectively suppressing tissue-destructive inflammation and have significant side effects, while existing mRNA regulation systems like RNA-binding proteins and miRNAs do not adequately function in sustaining chronic inflammation, leading to disease progression.

Innovation Solution

Development of artificial miRNA constructs with specific seed sequences that recognize RNA-binding protein motifs, adenine or uracil residues, and scramble sequences to regulate the expression of multiple target mRNAs involved in chronic inflammatory diseases, including cytokines and matrix-degrading enzymes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional anti-inflammatory drugs (steroidal and non-steroidal) are used, then inflammation is suppressed, but tissue-destructive inflammation cannot be effectively controlled and significant side effects occur

Engineering Contradiction:
Improveeffectiveness in suppressing inflammationVSAvoidside effects and insufficient tissue protection
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces conventional chemical anti-inflammatory drugs with an artificial miRNA-based molecular mechanism. The miRNA construct (5'-AUAAAUAAgccuccgggaucca-3') operates through post-transcriptional regulation of mRNA, specifically targeting and suppressing the expression of inflammatory cytokines and matrix-degrading enzymes at the mRNA level, thereby eliminating the need for conventional pharmaceutical chemicals and their associated side effects.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the mechanism of action from pharmacological suppression to molecular-level gene expression regulation. By designing an artificial miRNA with a specific seed sequence (5'-AUAAAUAA-3') that complements AU-rich elements in target mRNAs, the system achieves precise control over the expression parameters of inflammatory genes, allowing selective suppression without the broad-side effect profile of conventional drugs.

Inventive Principle:
Principle #35Parameter changes

2Ease of operation

If RNA-binding proteins and miRNAs are used to regulate mRNA, then post-transcriptional regulation is achieved, but these systems do not adequately function in sustaining chronic inflammation

Engineering Contradiction:
Improvepost-transcriptional mRNA regulation capabilityVSAvoidadequacy in suppressing chronic inflammation
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent employs preliminary action by designing an artificial miRNA construct that proactively targets and suppresses mRNA transcripts of inflammatory cytokines and matrix-degrading enzymes before they can be translated into functional proteins. The miRNA construct (5'-AUAAAUAAgccuccgggaucca-3') is introduced into cells where it immediately begins suppressing target gene expression, preventing the sustained chronic inflammation that occurs with conventional therapies.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The artificial miRNA construct exhibits multi-functionality by simultaneously targeting multiple different mRNAs containing AU-rich elements, including cytokines (TNF-α, IL-1β, IL-6) and matrix-degrading enzymes (MMP-13, ADAMTS5). This universal targeting capability allows a single miRNA construct to suppress multiple pathogenic factors involved in chronic inflammation, overcoming the limitation of natural miRNA systems that typically target single genes.

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Duration of action of moving object

If existing mRNA regulation systems are used, then transient expression of inflammatory genes is achieved, but chronic inflammation persists due to inadequate regulation

Engineering Contradiction:
Improvetransient expression duration of inflammatory genesVSAvoidduration of chronic inflammation
Core Design Contradiction:
Duration of action of moving objectVSDuration of action of stationary object

Solution Approach 1:

The patent achieves continuity of useful action by introducing an artificial miRNA construct that continuously suppresses the expression of inflammatory genes over time. Unlike natural miRNA systems that provide transient regulation, the engineered miRNA (5'-AUAAAUAAgccuccgggaucca-3') maintains sustained suppression of target mRNAs, thereby preventing the persistence of chronic inflammation and extending the duration of therapeutic effect.

Inventive Principle:
Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The miRNA constructs provide a novel therapeutic approach by simultaneously suppressing the expression of multiple genes involved in chronic inflammation, reducing inflammation and tissue damage, while maintaining minimal basal immune function to minimize side effects.

Implementation Method 1

miRNAs are single-stranded RNAs of about 21 to 25 nucleotides which are not translated into proteins. They are incorporated into the RNA-induced silencing complex (RISC), recognize the 3' UTRs of target genes, and suppress protein production by destabilizing the target mRNA or suppressing its translation.

Methodology Applied
Scientific EffectBase pairing:

Data Source

PatentEP4667571A1Artificial mirna construct
Publication Date: 2025.12.24 INSTITUTE OF SCIENCE TOKYO
  • EP4667571A1 patent drawingFigure 1
  • EP4667571A1 patent drawingFigure 2
  • EP4667571A1 patent drawingFigure 3

AI summary

One of the objects of the present invention is to provide an artificial miRNA construct useful for post-transcriptional mRNA regulation. The present invention uses a miRNA construct having a sequence, the sequence consisting of: i) a seed sequence recognizing a binding motif of an RNA-binding protein; ii) an adenine or uracil residue located on the 5' side of the seed sequence; and iii) a scramble sequence located on the 3' side of the seed sequence, the scramble sequence having a sequence so that a GC content of the entire miRNA construct is 40-60%.